The earnings call reflected a company with a strong pipeline and financial position, with significant upcoming clinical milestones that could create substantial value. However, the continued net loss and competitive challenges in the obesity market were noted as areas of concern.

Company Guidance

During the recent Neumora Therapeutics Second Quarter 2025 Financial Results Conference Call, the company provided extensive guidance on its future strategic initiatives and clinical developments. Neumora highlighted its prioritization of obesity as the lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with plans to initiate clinical studies in the first quarter of 2026. The company expects up to six clinical data readouts over the next 18 months, including Phase Ib data for NMRA-511 in Alzheimer's disease agitation by the end of the year, and top-line data from the Phase III KOASTAL program with navacaprant in major depressive disorder anticipated in early 2026. Additionally, Neumora disclosed a robust financial standing with $217.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025, supporting operations into 2027. The company aims to leverage its expertise in neuroscience to address prevalent brain diseases and improve patient outcomes, while maintaining a strong development pipeline.

Pipeline Prioritization

Neumora has prioritized obesity as the lead indication for NMRA-215, an NLRP3 inhibitor with high CNS penetration, citing the potential for substantial improvements over current therapies.

Strong Financial Position

The company ended the quarter with $217.6 million in cash, cash equivalents, and marketable securities, with a cash runway projected to support operations into 2027.

Upcoming Clinical Milestones

Up to six clinical data readouts are expected over the next 18 months, including Phase I and Phase Ib studies for several assets and Phase III data for navacaprant in major depressive disorder.

Positive Preclinical Developments

Preclinical models are showing promise, particularly for NMRA-215, with potential for highly compelling data in diet-induced obesity models expected later in the year.

Neumora Therapeutics, Inc. (NMRA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NMRA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.33 / -	-0.45	―	―	―
Aug 06, 2025	2025 (Q2)	-0.36 / -0.33	-0.37	10.81% (+0.04)	―
May 12, 2025	2025 (Q1)	-0.37 / -0.42	-0.34	-23.53% (-0.08)	―
Mar 03, 2025	2024 (Q4)	-0.42 / -0.37	-0.71	47.89% (+0.34)	―
Nov 12, 2024	2024 (Q3)	-0.39 / -0.45	-1.14	60.53% (+0.69)	―
Aug 06, 2024	2024 (Q2)	-0.37 / -0.37	-0.278	-33.09% (-0.09)	―	―
May 07, 2024	2024 (Q1)	-0.34 / -0.34	-0.234	-45.30% (-0.11)	―	―
Mar 07, 2024	2023 (Q4)	-0.55 / -0.71	-0.185	-283.78% (-0.52)	―	―
Nov 01, 2023	2023 (Q3)	-0.35 / -1.14	-0.193	-490.67% (-0.95)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NMRA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$1.59	$1.65	+3.77%
May 12, 2025	$0.69	$0.68	-1.45%
Mar 03, 2025	$1.56	$1.40	-10.26%
Nov 12, 2024	$13.64	$11.31	-17.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neumora Therapeutics, Inc. (NMRA) report earnings?

Neumora Therapeutics, Inc. (NMRA) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is Neumora Therapeutics, Inc. (NMRA) earnings time?

Neumora Therapeutics, Inc. (NMRA) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NMRA EPS forecast?

NMRA EPS forecast for the fiscal quarter 2025 (Q3) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing